Product Description
Mechanisms of Action: MMP Inhibitor,Collagen Inhibitor,Angiogenesis Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | European Medicines Agency | India | Norway | Poland | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Processa Pharmaceuticals
Company Location: HANOVER MD 21076
Company CEO: David Young
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Muscular Dystrophy, Duchenne|Pneumonia|COVID-19|Sarcoma, Kaposi
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PJS-539 | P2 |
Completed |
COVID-19|Pneumonia |
2022-02-03 |
|
| HALO-DMD-03 | P2 |
Terminated |
Muscular Dystrophy, Duchenne |
2016-12-30 |
|
| HALO-DMD-02 | P2 |
Terminated |
Muscular Dystrophy, Duchenne |
2016-04-30 |
24% |
| HALO-DMD-01 | P2 |
Terminated |
Muscular Dystrophy, Duchenne |
2016-03-30 |
24% |